BillionToOne detects genetic disorders in the baby through a simple blood test of the mother. Our first test for beta-thalassemia and sickle cell disease is already in clinical trials. These are the most common genetic disorders in the world, and their prenatal detection currently requires invasive methods with high miscarriage risk. More than 100 million people are carriers for these disorders. By being able to detect both large chromosomal disorders as well as single gene disorders at much lower costs, we aim to make prenatal genetic testing available for all, including in developing countries.
BillionToOne has raised funding from institutional funds and VCs such as Y Combinator, Fifty Years, Uphonest Capital, Civilization Ventures as well as from prominent angel investors who previously invested in SpaceX, Box, and Palantir.